A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia
This clinical trial is a multicenter, single-arm, open-label study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of olutasidenib administered orally twice daily under fasting conditions for one cycle of 28 days in at least 3 Japanese patients with relapsed or refractory IDH1 mutation-positive AML.
Japanese patients who personally provide written informed consent to participate... [+3]
Patients with IDH2 mutations or patients with a history of IDH2 inhibitor treatm... [+2]